Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET) Abstract #332

Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Aim(s): Impact of baseline Ki-67 index and other baseline characteristics on outcome was evaluated in a phase 3 trial of SU in pts with pancreatic NET.
Materials and methods: A total of 171 pts with pancreatic NET were randomized (1:1) in a double-blind trial of SU v. placebo (PBO). Ki-67 index was collected for exploratory analyses among those pts for whom it was available. Subgroup analyses of progression-free survival (PFS) by Ki-67 index and other baseline factors, including prior treatments (Tx), were performed.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result